Clinicopathologic features associated with efficacy and long‐term survival in metastatic melanoma patients treated with <scp>BRAF</scp> or combined <scp>BRAF</scp> and MEK inhibitors

Abstract

Long-term survival occurs for a minority of patients receiving MAPK inhibitor treatment alone. Sex, serum LDH, BRAF genotype, and primary melanoma ulceration status are independent factors associated with treatment outcomes. Patients with a complete response to treatment have the best survival, but relapses still occur.